ArticleTranslational cancer research2023
A novel eight-gene Immune Cell-Associated Predictive Gene model to predict recurrence in triple-negative breast cancer.
Article in Translational cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumour tissue contains not only tumour cells but also some stromal cells and immune cells. This is one composition of the immune microenvironment of the tumour and causes a significant effect on the prognostic factors and recurrence of malignant tumor. Methods: In this research, single-cell RNA data from triple-negative breast cancers (TNBCs) were comprehensively analyzed and 1,527 marker genes expressed in immune cells were identified. Subsequently, RNA sequencing and clinical data from 360 patients in the Triple Negative Breast Cancer database at the Fudan University Shanghai Cancer Center (FUSCC) were divided into two groups in a 1:1 ratio, the training group and the validation group. An eight-gene Immune Cell-Associated Predictive Gene (ICAPG) model for predicting breast cancer (BC) recurrence was developed using mRNA data from the training group combined with immune cell marker genes. Based on this model, subjects were divided into two different risk level groups. The predictive power of the model was fully validated using the validation group and The Cancer Genome Atlas (TCGA) database. The localization and expression of these eight genes were then confirmed in a single-cell database. ssGSEA and CIBERSORT algorithms were used to characterize the differences in immune cell infiltration between the two different risk groups. Results: The eight-gene ICAPG model was proven to be effective in the validation group. The low-risk group patients presented higher criterion of infiltration of CD8 Conclusions: This research established a new predictive model on the basis of immune cell marker genes that might effectively predict relapse in TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.